Key Takeaways NVO expanded its partnership with Aspect to develop potentially curative cell therapies for diabetes.Aspect will lead development and manufacturing, while NVO keeps options for later-stage involvement.The deal adds equity funding, milestones and royalties, giving NVO long-term upside if therapies succeed.Novo Nordisk (NVO) and Aspect Biosystems announced that they are advancing their partnership into a new phase focused on developing next-generation cellular medicines for diabetes.The companie ...